Role of Orth Biologics in Core Decompression for Femoral Head Preservation in Early Avascular Necrosis of Hip

Mohit Dadlani a*≡

a Department of Orthopaedics, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Wardha, India.

Author contribution
The sole author designed, analyzed, interpreted and prepared the manuscript.

Article Information
DOI: 10.9734/JPRI/2021/v33i60B34697

Open Peer Review History:
This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/80198

Received 15 October 2021
Accepted 20 December 2021
Published 23 December 2021

ABSTRACT

Head preserving procedures for Early Avascular Necrosis of hip are invariably effective in early stage. Core decompression (CD) is mostly performed modality for early stages of AVN having different success rates. Current review aims at determining efficiency of Bone marrow aspirate concentrate, Platelet rich Plasma, Bone morphogenic proteins and combining it with Core Decompression for early AVN stage, before femoral head collapse. To preserve a femur head damaged by osteonecrosis, treatment options should be applied early in the disease process for best results. When the articular cartilage becomes deficient to nutrients, it become more difficult to save a particular femur head, and eventually bone destruction occur, affecting hip biomechanics; articular changes eventually develop, necessitating arthroplasty or arthrodesis. Other early treatment techniques has been identified & improved to improve femur head survival & delay replacement. Analysis of 20 studies published between 2011 and 2020 was done of which 6 were retrospective & 14 were prospective. PRP showed better survival and functional outcome, however 3 studies showed inconclusive evidence for its regular usage. BMAC enhanced efficiency of CD & cell increment or combination of PRP for growth stimulation. Concluding, CD and BMAC worked effectively that CD only before femoral head collapse. But, PRP need more evidences for extensive utilization. Adding PRP to BMAC or culturing it would increase potency of CD with BMAC. Less data is available to assess efficiency of BMP-7 & role of Intraosseous bisphosphonate therapy could be studied for inexpensive & better alternate.
1. INTRODUCTION

Femur head AVN is progressive intraosseous condition leading to limitation of function as condition progress [1]. There is subchondral damage radiologically, which leads to support loss to femoral head joint surface, further leading to subchondral collapse & femoral head distortion [2-5].

The etiology of atraumatic osteonecrosis hip includes steroid, alcohol, coagulopathies, and others resulting in decreasing mesenchymal stem cells & increasing quantity of adipose cells & apoptotic cells, according to studies conducted over the last decade and a half [6-8]. It causes a mismatch between bone synthesis & osteolysis, resulting in loss of bony trabeculae. As a result, the articular cartilage's subchondral support is compromised, resulting in subchondral collapse, head deformation, altered hip biomechanics, & arthritis.

The goal of core decompression is to relieve intraosseous pressure & enhance blood supply to femur head in order to slow/stop progression of osteonecrosis. It had shown promise for the early phases of osteonecrosis, allowing for blood vessel growth & restoration of vascularity. CD only has shown promising outcomes in FICAT Stage 1, the success of similar technique in succeeding stages falls[9-11]. As a result, adjuvants are required to boost efficiency in further stages.

Transtrochanteric rotational and varus or valgus osteotomies transfer sick region of head away from weight bearing area in early stages of disease process, allowing unaffected portion to take its place; they have previously been reported to preserve the damaged head [12,13]. The outcomes of these procedures have been mixed, and their use has fallen in recent years [13].

Fibular & vascular grafts have been added with CD with better results, however they're difficult operations to execute. Newer orthobiologics, are progressively investigated in last 10-12 years; CD has been augmented with BMAC, PRP, & BMP-7 to boost the success rates [14-17]. Less studies [18, 19] had looked at them in the later stages.

Goal of systematic review is to evaluate efficiency of current orthobiologics to core decompression for head preserving in early stages of osteonecrosis & to search literature for any new therapy that might improve their survival chances in new century. In order to improve the findings, we looked into other ways to administer these adjuvants.

2. METHODOLOGY

2.1 Study Design

According to the PRISMA standards [20], systematic evaluation of literature is conducted using specific search engine such as Pub-Med and scopus.

2.2 Inclusion and Exclusion Criteria

Surgical methods for preserving the femur head damaged by AVN were included in study. We focussed mostly on CD & adjuvants used in conjunction with CD that improve femoral head survival rates in pre-femur head collapse stages of AVN. PRP & BMAC orthobiologics were perfectly recognised & included in study describing their use. Excluded studies included patients with extensive head deformation & arthritis alterations. Any studies published before 2011 were eliminated, including cadaveric investigations. Articles written in other languages were also excluded.

2.3 Data Collection and Analysis

Data was plotted on a table that contained the authors' names, year of publication, pertinent demographic information, study type, & outcome measures of relevance.

3. RESULTS

Total hits in both databases using our chosen keywords were 569, of which 288 studies were identified for further investigation. 46 studies were chosen after a review of titles and abstracts, and complete texts were examined. Finally, 20 studies [21-40] were included (all published between 2011 and 2020).

3.1 Characteristics of Studies

This review comprised a total of 20 studies, which were tabulated [21-40]. There were 14
prospective studies [33, 39, 21, 22, 23, 24, 27, 28, 29, 30, 31, 35, 36, 37] and six retrospective studies [25, 26, 32, 34, 38, 40]. Three investigations on the use of PRP with CD were published, one of which was a randomised study [21]. 14 studies looked at effectiveness of BMAC as a CD adjuvant [24-37], while one looked at the use of recombinant BMP-7 [40]. The results of employing both BMAC & PRP with CD were assessed in the remaining two investigations [38, 39].

In the studies covered, total 665 cases having 846 hips affected by AVN were included, with 295 cases being male & 195 being females. 3 studies [23, 31, 38] didn’t divide patients by gender (n 1/4 93 patients), while three others [28, 29, 33] did so depending on number of hips performed (M 1/4 78; f 1/4 26). In general, there was a significant male preponderance in the research that were considered.

In individual research, lowest number of cases were four [23], but greatest were hundred [37]. Average age of patients in the study was 37 yrs, demonstrating frequency of early osteonecrosis in young people & need for procedures such as arthroplasties to prevent progression. The average age of the patients in two trials [23, 28] was not mentioned. In the trials, the average follow-up length ranged from 9 months to 6 years.

**3.2 Core Decompression + PRP**

When compared to normal circulation, PRP is plasma with a higher number of platelets [41]. The platelets have many growth factors, that are released post treatment & aid in tissue growth and development. Theoretically, if CD lowers intrasosseous pressure, growth factors may aid in growth & bone formation, reducing complaints & potentially reversing/postponing disease progression. In current study, three studies looked at the impact of PRP with CD (Table I). While CD procedure differed from study to study, the therapy principle remained the same. In a randomised control experiment, Xian et al. used PRP with CD to treat 24 cases with early AVN. They compared them to 22 CD-only patients [21]. Both groups received autologous bone grafts, with a three-year minimum follow-up.

Despite the fact that both groups improved their HHS, PRP group had higher clinically important increase. At last follow-up, the HHS and VAS scores too favoured PRP group (P 1/4 0.024 and 0.0125, respectively). 3 cases in PRP group required THR, whereas 7 individuals in another group had to undergo procedure owing to arthritis. PRP is a successful adjuvant to CD for early stages of AVN, according to the authors' findings.

In 40 hips of 30 patients, Samy et al. used another procedure for decompression: they did anterior dislocation, and drilled several holes [22]. To keep the adjuvant in place, they injected bone graft combined with PRP & coated area with fibrin glue. At follow up, HHS became 90.3 as compared to preoperative HHS, with 36 patients having better score. THR was presented to the remaining four. In addition, the VAS score improved dramatically (P 0.0001).

Guadilla et al. studied CD using arthroscopy & under C arm, as well as the effects of CD using graft & PRP in 4 cases with AVN hips [23]. By the fifth month after surgery, all 4 cases had a sixty percent improve in pain intensity and were able to resume normal lives. Authors described a procedure that involved accessing femur head from base when hip was flexed to 10 to 15 degrees and the hip was in a neutral coronal plane with mild traction. A Steinmann pin (3.2mm) was used to drill numerous holes through anterior/accessory port. PRP was infiltrated into channel that had been formed.

**3.3 Core Decompression + BMAC**

Mono-nuclear stem cells, which are building blocks of hip's skeletal anatomy, are found in bone marrow aspiration concentrate (BMAC). They develop into bone-forming cells replacing old, faulty cells, preserving structural balance & integrity [16-19]. Introducing fresh pool of lineage cells capable of differentiating into cells required for hip's normal physiology appears to be promising therapy option for pre collapse phases of AVN. BMAC, MSCs, BMMCs had all be used to refer to the cells [24-28]. Several studies have looked into its use as a CD adjuvant, with great result (table II). Wang et al. used a combination of CD, curettage, bone transplant, and BMAC to treat 20 hips in 15 patients [24].
Table 1. Literature sources

| S.No. | Authors(year) (Study design) | AVN stages | Intervention | Number of patients,(Mean Age in years),(M:F) | Mean Follow up(months) | Final HHS, WOMAC scores | Final VAS score/pain | Survival/Arthroplasty conversion | Inference |
|-------|-------------------------------|------------|--------------|---------------------------------------------|------------------------|-------------------------|----------------------|-------------------------------|-----------------------|
| 1.    | Guadilla et al.(23) (2012) (Prospective case series) | Steinberg IIa, IIb | Arthroscopic Core decompression + ABG + PRP | 4 (NA) (NA) | 14 | NA | >60% significant improvement in all cases. |  | Procedure needs to be explored further. PRP increases reparable capacity after necrotic segment drilling. |
| 2.    | Samy et al.(22) (2016) (Prospective case series) | Modified Ficat IIb, III | Anterior dislocation + Removal of Necrotic area + Multiple drill holes + ABG mixed with PRP; covered with collagen gel and fibrin glue. | 30(40 hips) (36.7) (19:11) | 41.4 | HHS-90.28(p<0.0001) Excellent-27 Good-9 | 35(p<0.0001) | 4 patients with fair HHS-prepared for THR |
| 3.    | Xian et al.(21) (2019) (RCT) | Post traumatic:ARCO II, III | T/t:Core decompression (CD)+ PRP incorporated ABG, Control: CD + ABG | T/t: 24 Control:22 (T/t:28.3 Control:29.6) (T/t: 15:9 Control:10:12) | T/t:44.9 Control:46.2 | HHS: T/t:86.5 Control:79.3 (p=0.0254) | Significantly better in T/t group(p=0.125) | T/t: 3 THR Control: 7 THR; 2 transtrochanteric osteotomies | PRP is an effective adjuvant to CD + ABG |
| S. No. | Authors(year) (Study design) | AVN stage | Intervention | Number of patients,(Mean Age in years),(M:F) | Mean Follow up(months) | Final HHS, WOMAC scores | Final VAS score/pain | Survival/Arthroplasty conversion | Inference |
|-------|-----------------------------|-----------|--------------|---------------------------------------------|-----------------------|--------------------------|-----------------------|------------------------|-----------|
| 1     | Gangji et al. [30], (2011)  (Prospective) | ARCO I, II | T/t: CD + BMAC Cntrl: CD | 19 (24 hips) • 13 hips and 11 hips (42.2 45.7) (10:9) | 60 | Overall WOMAC score did not differ (pain part was significantly worse in control group; \( P < 0.05 \)) | Lesser VAS in T/t group (\( P = 0.009 \)) | Progression to Stage III more in cntrl group (\( P = 0.038 \)) Time to failure better in BMAC group. THR: T/t : 2 Cntrl: 3 | Long-term study suggests BMAC implantation in early AVN is effective |
| 2     | Sen et al. [28], (2012) (RCT) | ARCO I, II | Gp A: CD; Gp B: CD + BMAC (mononuclear) | 40 (51hips) • A: 25 hips • B: 26 hips (-) (A-18.7 B-19.7) | 24 | HHS | - | Better survival in B (\( P < 0.0351 \)) | Marked improvement with CD+BMAC specially in patients with poor prognostic features |
| 3     | Zhao et al. [37], (2012) (RCT) | ARCO I, II | CD versus CD with trephine + bore graft + BMAC (cultured & expanded) | 100 (104 hips) • 50 patients in each gp (51 and 53 hips) (33.8 32.7) (26.24 27.23) | 60 | Significantly better HHS in second group | - | 10 worsened (5 THR) 2 worsened (no THR) \( P < 0.05 \) | Functional scores and necrotic volume of femoral head had better outcomes with BMAC |
| 4     | Rastogi et al. [31], (2013) (Prospective clinical trial) | ARCO I, II, III | • Group 1: CD + BMAC (mononuclear cells) • Group 2: CD + unprocessed BMA | 40 (60 hips) • 30 hips in each group (34.67 33) (NA) | 24 | Improvement in HHS • Gp 1-31.85 • Gp 2-19.72 (\( P = 0.03 \)) | - | No THR 3 THR ARCO I, II; showed improved radiology | BMAC is safe and effective with better outcome than unprocessed aspirate in early AVN |
| S. No. | Authors(year) (Study design) | AVN stage | Intervention | Number of patients,(Mean Age in years),(M:F) | Mean Follow up(months) | Final HHS, WOMAC scores | Final VAS score/pain | Survival/Arthroplasty conversion | Inference |
|-------|-------------------------------|-----------|--------------|---------------------------------------------|------------------------|--------------------------|------------------------|------------------------|-----------|
| 5     | Liu et al. [32], (2013) (Retrospective series) | ARCO I, II, IIIA A: CD + BMMC + filler B: CD + filler | • 34 (53 hips) A: 26 hips B: 27 | 26.8 24.8 | Group A had more increase in HHS (28.6; $P < 0.001$) | VAS decreased more in Group A ($P = 0.004$); 6 hips showed collapse (4 THR) Group B: 16 collapses (5 THR) | Higher success rate in Group A ($P = 0.004$); 6 hips showed collapse (4 THR) | Addition of BMCC makes CD + Filler more effective |
| 6     | Wang et al. [24], (2014) (Prospective) | ARCO II, III CD + curettage + ABG + BMAC (mononuclear cells) | 15 (20 hips) (35) (10:5) | 24 | • HHS 85 • Excellent : 7 • Good : 8 • Fair : 4 • Poor : 1 | N/A 80% survival; 4 hip worsened but no THR | Effective procedure in early stages |
| 7     | Tabatabaei et al. [29], (2015) (Prospective randomized trial) | ARCO I, II, III A: CD + BMAC B: CD | • 18 (28hips) A: 14 B: 14 | 24 | Better WOMAC in Group A ($P < 0.001$) Mean score significantly lower in Group A | 3 THR in group B; none in group A | Combination is more effective in early stages than only CD |
| 8     | Pepke et al. [33], (2016) (Randomized clinical trial) | ARCO II CD versus CD + BMAC | • 24 (25 hips) CD-14 CD + BMAC-11 | 24 | Comparable HHS in both groups VAS decreased in both groups ($P < 0.05$) No difference in survival | No difference with BMAC as an adjuvant to CD in short term | |

---

N/A = Not Available
| S. No. | Authors(year) | AVN stage | Intervention | Number of patients,(Mean Age in years),(M:F) | Mean Follow up(months) | Final HHS, WOMAC scores | Final VAS score/pain | Survival/Arthroplasty conversion | Inference |
|-------|----------------|------------|--------------|-----------------------------------------------|------------------------|--------------------------|-----------------------|-----------------------------|-----------|
| 9     | Nally et al. [34], (2017) (Retrospective series) | Ficat I, II | 1. CD | • 33 (47 hips) | 72 | - | - | • Survival- 56% | No difference in any of the groups |
|      |                |            | 2. CD + BG | • 27 (34 hips) | 48 |               |                      | 50% | |
|      |                |            | 3. CD + BMAC | • 12 (16 hips) | 72 |               |                      | 50% | (no significant difference) |
|      |                |            | (38 40 41) | (24·9 21·6 8·4) | | | | | |
| 10    | Einhorn et al. [27], (2017) (Prospective series) | ARCO I, II | CD + BMAC | 52 (66 hips) | 24 | • Total score improved63% ($P < 0.001$) | • Survival of 75% (41/55 hips) | 11 lost to follow up. | CD + BMAC is a promising option for early AVN hips. |
|      |                |            | (40) | (29:23) | | • SF-12 scores and EQ-5D improved ($P < 0.001$) | 65% improvement in pain(as per WOMAC subcategory score) | | |
| 11    | Tomaru et al. [25], (2017) (Retrospective) | JOA staging, I, II | CD + BMAC | 31 (40) | 69.5 | JOA walking & quality of life scores improved. ($P < 0.05$) | Pain scores decreased significantly ($P< 0.05$); 2 patients had pain on walking | 3 THR; 11 hips showed secondary collapse when lesions were large | Long-term outcomes were good with disease progression rate less than natural course |
|      |                |            | (19 12) | | | | | | |
| 12    | Talathi et al. [26], (2018) (Retrospective) | ARCO I, II | CD + BMAC | 28 (43 hips) | 16 | 2.5 (significant decrease, $P < 0.0001$) | 3 THR (after average of 17 months) | CD + BMAC provides significant pain relief and arrests progression | |
|      |                |            | (40.1 13:5) | | | | | | |
| 13    | Mardones et al. [36], (2019) (Prospective cohort) | Ficat II, III (n = 4 and 1); <50% | CD + BMAC (ex vivo expansion) | 5 (41.2 4:1) | 33.8 | MHHS: from 73.6 to 98.2 | From 4.6 to 0.4 | No THR | MSC-based therapy is safe and effective in early stages |
| S. No. | Authors(year) (Study design) | AVN stage | Intervention | Number of patients,(Mean Age in years),(M:F) | Mean Follow up(months) | Final HHS, WOMAC scores | Final VAS score/pain | Survival/Arthroplasty conversion | Inference |
|--------|-----------------------------|-----------|--------------|---------------------------------------------|------------------------|------------------------|----------------------|-----------------------------|-----------|
| 14     | Wu et al. [35], (2020) (Prospective series) | ARCO II head involved | CD + BMAC (mononuclear cells) in collagen sponge | 30 (30.6) (19:11) | 9 | HHS 84.66±6.97 (P < 0.05) | 1.91±0.53 (P < 0.05) | Mean repair ratio better in patients receiving BMAC with better differentiation | Quality of stem cells determine success of the method |
| 1      | Martin et al. [38], (2013) (Retrospective) | Ficat I, II | CD + BMAC + PRP | 49 (77 hips) (43) (1) | 17 | - | 86% had significant pain relief | 16 THR | Provides significant pain relief and halts disease progression in early AVN |
| 2      | Houdek et al. [39], (2018) (Prospective) | UOP Stage I, II | CD + BMAC + PRP | 22 (35 hips) (43) (11:11) | 36 | HHS 85±15 (P < 0.0001) Excellent - good: 78% hips | - | 84% survival; collapse in 7%; 4 THR; 2 bilateral patients needed repeat CD | Successful results of >90%; better when necrotic area was smaller at early stages. |

Table 3. Growth factor
Tomaru et al. looked examined 31 AVN patients who were treated with CD and BMAC over the course of 5.8 years [25]. Eleven of the 31 hips having greater regions of damage collapsed, necessitating hip replacement in 3 cases. Authors claimed their collapse rate in hip having a larger region of damage was lower in other studies’ course of identical AVN. Overall, the study found that CD and BMAC is less invasive technique having great results in early stages of Avascular necrosis.

At follow-up of 64 weeks, Talathi et al. used the approach for forty three hips of twenty eight cases & saw substantial drop in VAS score [26]. 78% of cases said their pain had decreased by more than half, and serial radiographs revealed that 40 hips had not progressed. At average of 17 mths post surgery, three occurrences of femur head collapses necessitated arthroplasty. According to the authors, this technique could halt disease development and give significant symptom alleviation.

Einhorn et al. combined core decompression and BMAC in 66 hips from 52 patients & found a 63 percent improving overall WOMAC score [27]. Symptoms reduced dramatically, and quality of life scores (SF-12 and EQ-5D) increased significantly as well (P< 0.001). With exception of 11 hips lost to follow-up, hip survival was 75% (41/55), with only 14/55 hips requiring THR. Authors described core decompression with BMAC as a worthwhile method in Stage 1 & 2 AVN hips because of the overall positive outcome. However, whereas CD alone has been demonstrated to particularly effective in Stage 1 instances, BMAC should be utilised in following stages if possible.

Several Level 1 randomised clinical trials comparing CD & CD with BMAC in the early stages of AVN hip have also been undertaken. Sen et al. utilised BMAC as adjuvant in other 26 hip and performed CD in 25 of them [28]. The cases demonstrated significant improvement in HHS after a 2-year follow-up, with BMAC grp having better outcome at 1 yr follow-up (P <0.016). On two year follow-up, the BMAC group exhibited higher improvement in pain and deformity domains. The Kaplan Meier survival revealed that average survival rate in two groups were 46.72 and 51.85 weeks (P <0.0351). After two year of follow up, authors didn’t disclose number of further failure or THR performed. Surprisingly, individuals with less HHS & bad radiological appearance pre-operatively had higher hip survival rate with BMAC, according to the investigators.

Tabatabae et al. separated 18 cases (28 hip) in two group, each with 14 hips, & noted BMAC cases were having good WOMAC score (p <0.001) and VAS score at two years [29]. CD only group had 3 cases which required THR. For early AVN hips, the authors claimed that the combination of CD and BMAC was superior to CD alone.

Gangji et al. earlier reported similar findings in ARCO I and 2 stage AVN hip, with average 5 yr follow up, comparing CD with BMAC (13 hip) and CD only (11 hip) in ARCO 1 & 2 stage of AVN hip [30]. VAS score (P 1/4 0.009) and pain score of the WOMAC score (P <0.052) was considerably bad in the CD only group, despite the fact that the overall WOMAC scores were not different. With 8/11 hips in the CD alone group, disease progression to Stage III was more significant, compared to only 3 of 13 hip in BMAC group (p 1/4 0.038). BMAC infiltration as adjuvant to CD is also a more effective treatment modality than only CD, according to this long-term study.

Rastogi et al. [31] adjusted the CD only group as compared to prior research by adding unprocessed BMAC with CD in 1 group & BMMCs with CD in other (n 1/4 30 hips in both group). Their results demonstrated improved HHS in both groups after a two-year follow-up, although it is significantly better in group of BMMC (P 1/4 0.03). The unprocessed bone marrow group had three THRs, while the BMMCs group had no hips that required THR. In the ARCO I and II cases, size of lesions in BMMC group dropped (P 1/4 0.03). Technique was described as safe and successful in the early stage of AVN.

Liu et al. divided AVN patients into two groups, treating one group (26 hips) with nano hydroxyapatite or polyamide filler and the other group (27 hips) with BMMC [32]. When two groups were compared, it was shown that patients who took BMCC had higher percentage gain in their score (28.660.5%) than the other group (18.461.7%), P< 0.001. Similarly, improvements were reported in overall VAS ratings, with the BMMCs group (66.361.4 percent) showing a greater reduction (p< 0.001) than the other group (51.762.9 percent). The authors defined clinical success as a proportion of patients in either group with an HHS of 80 or greater, which was similarly higher in the BMMCs
group (75.4 percent versus 37 percent). Furthermore, in this group, radiographic head collapse and the onset of the osteoarthritic stage were much lower (21.4 percent versus 59.3 percent failure). The authors suggested that using BMMCs as an adjuvant treatment for early AVN could be more successful than using CD alone.

There have also been reports that BMAC with CD has no further benefits. In a randomised clinical trial, Pepke et al. compared CD and CD with BMAC in 24 patients with 25 hips in ARCO I and II stages (14 and 11 hips in both groups, respectively) [33]. Patients in both groups had comparable HHS and considerably lower VAS ratings from pre-operative values at a 2 year follow up (p < 0.05). Survival rates did not differ in groups, with 8 & 7 instances in each group not advancing or requiring THR. Overall, the authors found no evidence of BMAC's enhanced efficacy as a CD adjuvant.

In Ficat phases I and II, Nally et al. compared 3 groups: CD (47 hips), CD with bone graft (34 hips), & CD with BMAC (16 hips) [34]. They looked examined the differences in converting THR & discovered that rates of conversion to THR didn’t differ (p 1/4 0.2), with 48 instances (49.5 percent) requiring it after five year follow up. At a four-year follow-up, 50% of patients who got BMAC (MSC) required THR. Overall, adding MSC or a bone graft to CD had no effect on the survival of afflicted hips. The quality of BMAC/MSCs could be one explanation for these research producing contradictory result.

After average 9 month follow up, Wu et al. studied 30 cases with CD by 6.5 mm drill, curetting, & BMAC soaked in collagen gauze & found substantial progress in HHS & VAS (HHS-84.66, VAS- 1.91; p<0.05) [35]. MRI used to assess the necrotic region, and the ratio of repair was computed by dividing difference between the area before & after nine months after surgery by area before operation, then multiply result by hundred. At 9 months, necrotic area ratio has decreased significantly from 35.51 - 13.74 percent. Mean ratio of repair was 62.263 %, & it was positively connected with improvement of HHS, implying that the more repair radiologically, the better is outcome functionally. Furthermore, BMAC cells from patients having a higher ratio of repair was showing stronger stain for osteogenic & chondrogenic development, which is likely what decides the final outcome of BMAC therapy in AVN hip.

Given the conflicting data on the utility of BMAC/MSC, treatments were created for improving content quality of these cells prior to infiltration to patient. In five cases, Mardones et al. enhanced volume of MSC in BMAC by growing & expanding them ex-vivo & injecting them through CD tract [36]. Modified HHS scores improved significantly (mean 1/4 was 98.3) and VAS score reduced (from 4.6 - 0.4) in all 5 patients during a follow-up period ranging from 19 - 54 month. Despite small number of patients, no arthroplasty was required. In their experience, when non expanded stem cell was employed with CD, eighty percent of cases eventually required Hip Replacement, according to the scientists. It's worth noting that expanding the stem cells boosted their numbers, which were measured prior to instillation. In each hip, a minimum of 40106 cells were implanted.

CD (50 patients) was compared to CD + cultured BMAC with expanded MSC (50 patient) by Zhao et al. [37]. They told considerably better HHS in BMAC group after a 5-year follow-up. In addition, ten hips in the CD-alone group deteriorated radiologically (necrotic volume), with five of them requiring arthroplasty; just two hips in the BMAC group deteriorated further. The scientists came to the conclusion that a larger BMAC delivers a better functional outcome and slower disease development, as well as a higher chance of survival. As a result, cultured BMAC in combination with CD may be a viable alternative in the future.

When administered as an adjuvant, BMAC with MMNCs had shown to improve CD effectiveness. In the early stage of AVN, the vast majority of trials testing this combination showed excellent results, with symptomatic pain reduction & better functional outcome. Improving quality & quantity of these cells prior to infiltration could help achieve these therapeutic aims of hip survival even more.

### 3.4 CD + BMAC + PRP

By BMAC's mixed outcomes, the focus might be turning to increasing no. of bone formation cells. Aside from ex vivo cultivation of cells mentioned, adding growth agents to increase number of these cells could be viable option. Latter is accomplished by combining BMAC with PRP, which contain all of necessary growth factor.
Martin et al. used a CD, BMAC, & PRP combinations in forty nine patient with seventy seven hips & observed considerable pain reduction in 86 percent of patients after average follow up of 17 months [38]. THR was necessary in 16 of the 77 hips.

Houdek et al. treated twenty two patients of thirty five AVN hips as a result of steroid use with CD with BMMSC with PRP [39]. The survivability free of THR at two and three year follow up was ninety seven percent & eighty four percent, according to the findings. Only 4 hips required THR, with 2 bilateral patients requiring additional CD.

3.5 CD + rh-BMP-7

MSCs are stimulated by bone morphogenetic proteins (BMPs), which help them proliferate and differentiate into bone-forming cells. BMP-7 is a available product that is tested in non-union situations. Papanagiotou et al. employed recombinant (rh) BMP-7 with CD & non-vascularized fibular graft in seven hip of six cases [40]. The authors documented THR in 2 hips of bilateral cases after one year operation following mean follow up of four year. Clinically, other patients shown remarkable improvement, with both VAS & HHS values improvement dramatically. Femoral heads revealed nil evidence of flattening or collapsing on X rays taken at final follow up. Presence of heterotrophic ossification in four hips had nil clinical implications. So, treatment combination proved to be beneficial in slowing disease development and improving clinical outcomes.

Overall, recombinant BMP-7 has been used sparingly as a CD adjuvant in the last decade, owing to its limited availability and expensive cost. Although the lone trial evaluating its efficacy found significant improvements in all seven hips, the data is insufficient to endorse it as a useful adjuvant. More research is required to determine the utility.

3.6 Other Adjuvants—Bisphosphonates

Such pricey therapies become inaccessible in countries with high percentage of the people living below poverty line & no comprehensive insurance coverage. As a result, there is demand for cheaper adjuvants that could be administered to large number of patients. Bisphosphonates prevent bone loss caused by osteoclasts by triggering osteoclast death [42]. In theory, their ability to prevent bone death in osteonecrosis may be critical, and studies utilising bisphosphonates with both subcutaneous & enteral routes have shown promising result in early AVN [43, 44]. Therefore, it is necessary for targeting action of drugs to exact location where it is required; intraosseous route can be a viable approach for improving bisphosphonate effect in the diseased part [45-47].

Some studies had combined BMP-2 locally and intraosseous bisphosphonates to boost bone-forming cell proliferation. Further local infiltration of ibandronate & BMP-2 improved sphericity of femur head & accelerated healing of bone in piglets having ischemic osteonecrosis, according to Vandermeer et al. & Kim et al. [46, 47].

To summarise, it is likely that, in addition to CD, which stimulates new bone formation, a bisphosphonate such as ibandronate, injected intraosseously, will limit bone resorption. They are substantially less expensive than the rest of adjuvants mentioned, so if they are proven to be beneficial in combination with CD, they can benefit a large number of patients. This therapy technique is already being tested by the authors of this review.

3.7 Miscellaneous-Combination and Routes of administration

Aside from intraosseous administration, BMMCs can also be administered intra-arterially via the femoral artery. In thirty patients (24 male; 6 female) having AVN, Cai et al. instilled BMMC coupled with allogenic umbilical cord derived MSC [48]. This approach was used to treat 49 hips with AVN at ARCO 2 or 3 stage. Procedure included Digital Subtraction Angiography(DSA) and identifying one of 3 arteries: MCFA, LCFA, or obturator artery, with major one in femur head cannulated and cells injected within thirty minutes. Patient’s pain and function of joint improved as a result of the treatment. The HHS healed dramatically after a year, and forty four bone lesions on CT improved. They came to the conclusion that such treatment was safe option for AVN patients.

Chen et al. used solely MSC from cord for intra-arterial injections in 9 ARCO II & III cases (4 male & 5 female). Their MRIs showed that between 1 & 2 years, necrotic volumes dropped dramatically (7.1660.73 to 5.8661.67 cm3); the approach was also effective in boosting the HHS as compared preoperatively at one year [49].
Daltro et al. proposed method for injecting BMAC into a femoral head lesion that involved a percutaneous technique and single puncture by a 3 mm trocar under fluoroscopic supervision [50]. 89 patients were observed for five years, & their complains and HHS improved significantly from 75.8 - 93.2 (p 1/4 0.0005). 3 patients didn’t improve to their satisfaction, but their radiological phases did not progress.

Sun et al. studied use of recombinant BMP-2 with the 'Light bulb operation' [51]. The study included forty two patients with seventy nine hips in ARCO stages 1, 2, and 3A, with a follow up of 6 year. BMP-2 was given to 36 hips together with curettage and bone graft, while forty three hips got simply curettage & bone graft . HHS in the 1st group was 82.3613, while in the non-BMP group it was 78.9612. Stage 2 disease produced better results than Stage 3. 2 groups had survival rate of 81.9 and 71.9 percent, respectively, with Stage 3a having only 34.5 percent overall. Few of the related studies were reviewed[52-54].

4. CONCLUSION

The high frequency of hip AVN in a younger group necessitates early intervention to save the afflicted hip & postpone THR as long as possible. Core Decompression, in combination with available adjuvants such as BMAC, PRP, or their combination, is better and effective than Core Decompression alone for getting this therapeutic goal; but, the associated cost necessitate evaluation of other adjuvants & appropriate selection of patients in determining best routes of administration of the ortho-biologics, in order to improve the outcomes.

CONSENT

It is not applicable.

ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Author has declared that no competing interests exist.

REFERENCES

1. Lau RL, Perruccio AV, Evans HM et al. Stem cell therapy for the treatment of early-stage avascular necrosis of the femoral head: a systematic review. BMC Musculoskelet Disord 2014; 15:156.
2. Bozic KJ, Zurakowski D, Thornhill TS. Survivorship analysis of hips treated with core decompression for nontraumatic osteo- necrosis of the femoral head. JBJS 1999; 81:200–9.
3. Cheng EY, Thongtrangan I, Laorr A et al. Spontaneous resolution of osteonecrosis of the femoral head. JBJS 2004; 86:2594–9.
4. Hernigou P, Beaujean F. Treatment of osteonecrosis with autologous bone marrow grafting. Clin Orth Relat Res 2002; 405:14–23.
5. Hernigou P, Beaujean F, Lambotte JC. The decrease in the mesenchymal stem-cell pool in the proximal femur in corticosteroid-induced osteonecrosis. J Bone Joint Surg Br 1999; 81-B: 349–55.
6. Gangji V, Hauzeur JP, Matos C et al. Treatment of osteonecrosis of the femoral head with implantation of autologous bone marrow cells: a pilot study. J Bone Joint Surg Am 2004; 86:1153–60.
7. Phemister DB. Treatment of the necrotic head of the femur in adults. J Bone Joint Surg Am 1949 1; 31:55–66.
8. Mutijima E, De Maertelaer V, Deprez M et al. The apoptosis of osteoblasts and osteocytes in femoral head osteonecrosis: its specificity and its distribution. Clin Rheumatol 2014; 33:1791–5.
9. Fairbank AC, Bhatia D, Jinnah RH et al. Long-term results of core decompression for ischaemic necrosis of the femoral head. J Bone Joint Surg Br 1995; 77:42–9.
10. Iorio R, Healy WL, Abramowitz AJ et al. Clinical outcome and survivorship analysis of core decompression for early osteonecrosis of the femoral head. J Arthroplasty 1998; 13:34–41.
11. Yoon TR, Song EK, Rowe SM et al. Failure after core decompression in osteonecrosis of the femoral head. Int Orthop 2001; 24:316–8.
12. Sugioka Y, Hotokebuchi T, Tsutsui H. Transtrochanteric anterior rotational osteotomy for idiopathic and steroid-induced necrosis of the femoral head: indications and long-term results. Clin Ortop 1992; 277:111–20.
13. Rijnen WH, Gardeniers JW, Westrek BL et al. Sugioka’s osteotomy for femoral-head necrosis in young Caucasians. Int Orthop 2005; 29:140–4.
14. Zhou W, Qu M, Lv Y et al. New advances in stem cell therapy for osteonecrosis of the femoral head. Curr Stem Cell Res Ther 2019;14:226–9.
15. Alshameeri Z, McCaskie A. The role of orthobiologics in hip preservation surgery. J Hip Preserv Surg 2015; 2:339–54.
16. Piuazzi NS, Chahla J, Schrock JB et al. Evidence for the use of cell-based therapy for the treatment of osteonecrosis of the femoral head: a systematic review of the literature. J Arthroplasty 2017;32:1698–708.
17. Papavasiliou AV, Triantafyllopoulos I, Paxinos O et al. The role of cell therapies and hip arthroscopy in the management of osteonecrosis: an update. J Hip Preserv Surg 2018; 5:202–8.
18. Gagala J, Tarczynska M, Gaweda K et al. The use of osteochondral allograft with bone marrow-derived mesenchymal cells and hinge joint distraction in the treatment of post-collapse stage of osteonecrosis of the femoral head. Med Hypotheses 2014; 83:396–400.
19. Kang JS, Suh YJ, Moon KH et al. Clinical efficiency of bone marrow–derived mesenchymal stem cell implantation for the femoral head: a matched pair control study with simple core decompression. Stem Cell Res Ther 2018; 9:274.
20. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010; 8:336–41.
21. Xian H, Luo D, Wang L et al. Platelet-rich plasma-incorporated autologous granular bone grafts improve outcomes of post-traumatic osteonecrosis of the femoral head. J Arthroplasty 2020;35:325–30.
22. Samy AM. Management of osteonecrosis of the femoral head: a novel technique. Indian J Orthop 2016; 50:359–65.
23. Guadilla J, Fiz N, Andia I et al. Arthroscopic management and platelet-rich plasma therapy for avascular necrosis of the hip. Knee Surg Sports Traumatol Arthrosoc 2012; 20:393–8.
24. Wang T, Wang W, Yin ZS. Treatment of osteonecrosis of the femoral head with thorough debridement, bone grafting and bone-marrow mononuclear cells implantation. Eur J Orthop Surg Traumatol 2014; 24:197–202.
25. Tomaru Y, Yoshioka T, Sugaya H et al. Hip preserving surgery with concentrated autologous bone marrow aspirate transplant- ation for the treatment of asymptomatic osteonecrosis of the femoral head: a retrospective review of clinical and radiological outcomes at six years postoperatively. BMC Musculoskelet Disord 2017; 18:292.
26. Talathi NS, Kamath AF. Autologous stem cell implantation with core decompression for avascular necrosis of the femoral head. J Clin Orthop Trauma 2018; 9:349–52.
27. Einhorn TA, Anoushiravani AA, Chen KK et al. Treatment of stage I and II osteonecrosis of the femoral head with core decompression and bone marrow aspirate concentrate injection—a 2-year follow-up study. Sem Arthroplasty 2017; 28: 239–45.
28. Sen RK, Tripathy SK, Aggarwal S et al. Early results of core decompression and autologous bone marrow mononuclear cells instillation in femoral head osteonecrosis: a randomised control study. J Arthroplasty 2012; 27:679–86.
29. Tabatabaei RM, Saberi S, Parvizi J et al. Combining concentrated autologous bone marrow stem cells injection with core decompression improves outcome for patients with early-stage osteo- necrosis of the femoral head: a comparative study. J Arthroplasty 2015; 30:11–5.
30. Gangji V, De Maertelaer V, Hauzeur JP. Autologous bone marrow–cell implantation in the treatment of non-traumatic osteo- necrosis of the femoral head: five-year follow-up of a prospective controlled study. Bone 2011;49: 1005–9.
31. Rastogi S, Sankineani SR, Nag HL et al. Intralesional autologous mesenchymal stem cells in management of osteonecrosis of femur: a preliminary study. Musculoskelet Surg 2013;97: 223–8.
32. Liu Y, Liu S, Su X. Core decompression and implantation of bone marrow mononuclear cells with porous hydroxyapatite composite filler for the treatment of osteonecrosis of the femoral head. Arch Orthop Trauma Surg 2013; 133:125–33.
33. Pepke W, Kasten P, Beckmann NA et al. Core decompression and autologous bone marrow concentrate for treatment of femoral head osteonecrosis: a randomised prospective study. Orthop Rev (Pavia) 2016; 8:6162.
34. Nally FJ, Zanotti G, Buttaro MA et al. THA conversion rate comparing decompression alone, with an autologous bone graft or stem cells in osteonecrosis. Hip Int 2018; 28:189–93.
35. Wu ZY, Sun Q, Liu M et al. Correlation between the efficacy of stem cell therapy for osteonecrosis of the femoral head and cell viability. BMC Musculoskelet Disord 2020; 21:55.
36. Mardones R, Camacho D, Monsalvo F et al. Treatment of osteonecrosis of the femoral head by core decompression and implantation of fully functional ex vivo expanded bone marrow-derived mesenchymal stem cells: a proof-of-concept study. Stem Cells Cloning 2019; 12:11–6.
37. Zhao D, Cui D, Wang B et al. Treatment of early-stage osteonecrosis of the femoral head with autologous implantation of bone marrow-derived and cultured mesenchymal stem cells. Bone 2012; 50:325–30.
38. Martin JR, Houdek MT, Sierra RJ. Use of concentrated bone marrow aspirate and platelet-rich plasma during minimally invasive decompression of the femoral head in the treatment of osteonecrosis. Croat Med J 2013; 54:219–24.
39. Houdek MT, Wyles CC, Collins MS et al. Stem cells combined with platelet-rich plasma effectively treat corticosteroid-induced osteonecrosis of the hip: a prospective study. Clin Orthop Relat Res 2018; 476:388–97.
40. Papanagiotou M, Malizos KN, Vlychou M, Dailliana ZH. Autologous (nonvascularised) fibrular grafting with recombinant bone morphogenetic protein-7 for the treatment of femoral head osteonecrosis: a preliminary report. Bone Joint J 2014; 96-B: 31–5.
41. Gato-Calvo L, Magalhaes J, Ruiz-Romero C et al. Platelet-rich plasma in osteoarthritis treatment: a review of current evidence. Ther Adv Chronic Dis. 2019;10:1–18. DOI: 10.1177/2040622319825567
42. Fleisch H. Bisphosphonates: mechanisms of action. Endocr Rev 1998; 19:80–100.
43. Xie XW, Kang PD, Pei FX. Effect of alendronate and lovastatin in preventing early glucocorticoids-induced osteonecrosis of the femoral head in rats by micro-CT. Orthopedic J China 2013; 21: 82–6.
44. Fan M, Jiang WX, Wang AY et al. Effect and mechanism of zoledronic acid prevention of collapse in osteonecrosis of the femoral head. Zhongguo yi xue ke xue yuan xue bao 2012; 34: 330–6.
45. Aya-ay J, Athavale S, Morgan-Bagley S et al. Retention, distribution, and effects of intraosseously administered ibandronate in the infarcted femoral head. J Bone Miner Res 2006; 22: 93–100.
46. Vandermeer JS, Kamiya N, Aya-ay J et al. Local administration of ibandronate and bone morphogenetic protein-2 after ischemic osteonecrosis of the immature femoral head: a combined therapy that stimulates bone formation and decreases femoral head deformity. J Bone Joint Surg Am. 2011; 93:905–13.
47. Kim HK, Aruwajoye O, Du J et al. Local administration of bone morphogenetic protein-2 and bisphosphonate during nonweight-bearing treatment of ischemic osteonecrosis of the femoral head: an experimental investigation in immature pigs. J Bone Joint Surg Am. 2014; 96:1515–24.
48. Cai J, Wu Z, Huang L et al. Cotransplantation of bone marrow mononuclear cells and umbilical cord mesenchymal stem cells in avascular necrosis of the femoral head. Transplant Proc. 2014; 46:151–5.
49. Chen C, Qu Z, Yin X et al. Efficacy of umbilical cord-derived mesenchymal stem cell-based therapy for osteonecrosis of the femoral head: a three-year follow-up study. Mol Med Rep. 2016; 14: 4209–15.
50. Daltro GC, Fortuna V, de Souza ES et al. Efficacy of autologous stem cell-based therapy for osteonecrosis of the femoral head in sickle cell disease: a five-year follow-up study. Stem Cell Res Ther. 2015; 6:110.
51. Sun W, Li Z, Gao F et al. Recombinant human bone morphogenetic protein-2 in debridement and impacted bone graft for the treatment of femoral head osteonecrosis. PLoS One 2014; 9: e100424.
52. Pissukar, Gajanan, Kiran Saoji, Dhruba U. Angachekar, Mohit Dadlani, and Priyanshu Pandey. “Intraoperative Periprosthetic Fracture of Femur in a Case of Revision Total Hip Replacement: A Case Report.” Medical Science 2020;24(104)(August): 2691–99.
53. Pisulkari G, Date S, Saoji K, Belsare K, Saoji A, Surana K. A study of outcome in comminuted supracondylar femur fracture with bone loss treated with locking compression plating and fibular bone grafting. Medical Science. 2021 Feb;25(108):447–60.

54. Vaidya L, Bawiskar D, Upadhyay P, Phansopkar P. A Comprehensive Rehabilitation of a known Case of Leprosy Operated for Midshaft Femur Fracture. Journal of Pharmaceutical Research International. 2021;33(38A):299–306.

© 2021 Dadlani; This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history:
The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/80198